Working… Menu

Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients (PATSGO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00643825
Recruitment Status : Unknown
Verified July 2010 by Cliniques universitaires Saint-Luc- Université Catholique de Louvain.
Recruitment status was:  Recruiting
First Posted : March 26, 2008
Last Update Posted : July 23, 2010
Information provided by:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Brief Summary:
This study will test the hypothesis that prolonged adjuvant Temozolomide (TMZ) may delay relapses in patients with glioblastoma compared to the standard care consisting in observation with brain MRI every 3 months and rechallenging with TMZ at relapse (Stop and Go arm).

Condition or disease Intervention/treatment Phase
Glioblastoma Drug: Temozolomide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Multicentric Phase II Study of Prolonged Adjuvant Temozolomide or "Stop and Go" in Glioblastoma Patients: The PATSGO Study
Study Start Date : January 2008
Estimated Primary Completion Date : January 2011
Estimated Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: A: prolonged adj TMZ Drug: Temozolomide
Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD

B : Stop and Go
Rechallenging patients with TMZ at relapse
Drug: Temozolomide
Observation till Progression then rechallenging with TMZ

Primary Outcome Measures :
  1. to determine whether prolonged administration of Temozolomide in glioblastoma patients increase their progression-free and overall survival at 6 months [ Time Frame: 36 months ]

Secondary Outcome Measures :
  1. safety and adverse event profile of prolonged adjuvant Temozolomide [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with histologically confirmed diagnosis of GBM
  2. Availability of pre-treatment GBM tissue to determine the activation status of MGMT gene is not mandatory but strongly recommended
  3. Patients must have received radiation and TMZ for 6 weeks followed by 6 months of TMZ. Randomization should be performed within the 6 weeks after the last chemotherapy.
  4. A brain MRI with or without a PET-Scan-methionine must be performed before enrolment.
  5. Age ≥ 18 years
  6. Karnofsky Performance status ≥ 60
  7. Normal haematological functions: ANC ≥ 1.5 x 109cells/l, platelets ≥ 100 x 109 cells/l
  8. Normal liver function: total bilirubin < 1.5 x ULN, alkaline phosphatase and transaminases (ASAT/ALAT) < 2.5 times the upper limit of the normal range
  9. Serum creatinine < 1.5 x ULN
  10. Clinically normal cardiac function without history of ischemic heart disease in the past 12 months. Absence of cardiac insufficiency NYHA grade III and IV, instable angina, arrhythmia
  11. No previous or current malignancy (except treated basal or squamous cell skin carcinoma, cervix cancer or in situ carcinoma of the breast).
  12. All patients (male and female) with reproductive potential must use effective contraception. Females must have a negative serum pregnancy test at entry to study.
  13. Signed informed consent from the patient or legal representative must be obtained.

Exclusion Criteria:

All non inclusion criteria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00643825

Layout table for location contacts
Contact: Jean-Francois BAURAIN, MD, PhD +32 2 764 54 71

Layout table for location information
Cliniques Universitaires Saint-Luc Recruiting
Brussels, Europe, Belgium, 1200
Contact: Jean-Francois BAURAIN, MD, PhD    +32 2 764 54 71   
Sponsors and Collaborators
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Layout table for investigator information
Principal Investigator: Jean-Francois Baurain, MD, PhD Cliniques universitaires Saint-Luc
Layout table for additonal information
Responsible Party: Prof Baurain J-Fr, Cliniques universitaires Saint-Luc Identifier: NCT00643825    
Other Study ID Numbers: UCL-ONCO 06-004
First Posted: March 26, 2008    Key Record Dates
Last Update Posted: July 23, 2010
Last Verified: July 2010
Keywords provided by Cliniques universitaires Saint-Luc- Université Catholique de Louvain:
Phase II
Progression-free Survival
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents